Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
Latest Information Update: 11 Jun 2025
At a glance
- Drugs Iparomlimab/tuvonralimab (Primary) ; Olaparib (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 11 Jun 2025 New trial record